HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via ISI Web of Science (13) Citing Articles via Google Scholar Google Scholar Articles by Burns, C. J Articles by Jones, P. M Search for Related Content PubMed PubMed Citation Articles by Burns, C. J Articles by Jones, P. M

Beta Cell Development and Function Group, King’s College London, Hodgkin Building, Guy’s Campus, London SE1 1UL, UK

(Requests for offprints should be addressed to C J Burns; Email: chris.burns{at}kcl.ac.uk)

Type 1 diabetes can now be ameliorated by islet transplantation, although this treatment is restricted by the insufficient supply of islet tissue. The need for an essentially limitless supply of a substitute for primary human islets of Langerhans has led to research into the suitability of stem/progenitor cells to generate insulin-producing cells to use in replacement therapies for diabetes. Although there has been much research in this area, an efficient and reproducible protocol for the differentiation of stem cells into functional insulin-secreting ß-cells that are suitable for transplantation has yet to be reported. In this commentary we examine the minimum requirements for replacement ß-cells and outline some of the potential sources of these cells. We also argue that the generation of the ‘perfect’ beta-cell may not necessarily lead to the most suitable tissue for transplantation.